Table 1.
Study | No. of participants | Study population | Type of intervention | Risk reduction | Duration |
---|---|---|---|---|---|
Da Quing [Pan et al. (16)] | 577 | Chinese, mean age 45 years, BMI 26 kg/m2 | Diet, exercise | 31%–46% | 6 years |
STOP-NIDDMa [Chiasson etal. (21)] | 1429 | IGT adults, mean age 55 years, mean BMI 31 kg/m2 | Acarbose | 25% | 3.3 years |
Finnish DPS [Tuomilento et al. (18)] | 522 | IGT adults, mean age 55 years, mean BMI 31 kg/m2 | Diet and exercise | 58% | 3.2 years |
DPP [Knowler et al. (17)] | 3234 | IGT adults, mean age 51 years, mean BMI 34 kg/m2 | Diet and exercise, or Metformin | Metformin 31% | 2.8 years |
Lifestyle 58% | |||||
XENDOS [Orgerson et al. (22)] | 3305 | Swedish, BMI >30 kg/m2, mean age 43 years, 21% with IGT | Orlistat + diet + exercise | Entire group 37% | 4 years |
IGT subgroup 45% | |||||
DREAM [Hanley et al. (24)] | 5269 | IGT and/or IFG patients, mean age 54 years, BMI 30.9 kg/m2 | Rosiglitazone | 62% | 3 years |
STOP-NIDDM, Study to Prevent Non-Insulin-Dependent Diabetes Mellitus; DPS, Diabetes Prevention Study; XENDOS, XENical in the Prevention of Diabetes in Obese Subjects.